Laminar Pharmaceuticals  

Next generation medicines

OWNER

Javier Fernandez Diaz (See Profile)


Sector

Biotech

Stage

Development, market readiness, clinical trial

Country

España


Compound on phase-3 clinical trial to be approved in 2024 by EMA as next Standard of Care for glioblastoma patients.

Compound with Orphan Drug Designation (both by EMA and FDA) and Fast-Track Designation (FDA) for glioma. Market of 2B$.

Composition of matter patent and Freedom-to-Operate up until 2034. Evergreening strategy for further protection.

Status

Approved

IP Type

Patent

Time

11 years

Countries

Australia
Austria
Belgium
Canada
China
Denmark
Finland
France
Germany
Israel
Italy
Japan
Netherlands
Russia
South Korea
Spain
Switzerland
USA
United Kingdom

Coverage

The invention relates to alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug. More specifically, the invention relates to compounds having formula I, and the pharmaceutically acceptable derivatives and salts thereof, in which (a) and (b) can have any value between 0 and 14, (X) can be substituted by any atom or group of atoms with a weight between 4 and 200 Da, and (R) can be substituted by any atom or group of atoms with a weight between 1 and 200 Da, intended for use as a drug.

Know more of this patent

This information is confidential, do not share or copy.

Under evaluation at least till: 15th of May 2023

If you want to have more information or you want to review the project, you have to login or register

©2023 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar